Countable Labs introduced a single-molecule precision PCR platform aimed at improving rare-event detection and run-to-run reproducibility in applications such as viral titer testing, vector copy number measurement, and residual DNA impurity quantification for gene and cell therapies. The platform is designed to address limitations of standard PCR workflows, where many methods infer molecule counts using statistical models rather than direct counting. In low-abundance settings, that ambiguity can complicate thresholds for manufacturing and clinical decision-making. The innovation spotlight emphasized that more confident molecule counting can improve sensitivity and reproducibility when targets are present at trace concentrations, including minimal residual disease and circulating tumor DNA contexts. As gene therapy quality systems and analytical comparability requirements expand globally, more direct quantification tools like this are increasingly relevant for consistent batch release and cross-site monitoring.